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More than 70 missense mutations have been identified in the
human melanocortin 4 receptor (MC4R), and many of them
have been associated with obesity. In a number of cases, the
causal link between mutations in MC4R and obesity is con-
troversially discussed. Here, we mined evolution as an addi-
tional source of structural information that may help to eval-
uate the functional relevance of naturally occurring
variations in MC4R. The sequence information of more than
60 MC4R orthologs enabled us to identify residues that are
important for maintaining receptor function. More than 90%
of all inactivating mutations found in obese patients were
located at amino acid positions that are highly conserved dur-
ing 450 million years of MC4R evolution in vertebrates. How-
ever, for a reasonable number of MC4R variants, we found no
correlation between structural conservation of the mutated
position and the reported functional consequence. By reeval-
uating selected mutations in the MC4R, we demonstrate the
usefulness of combining functional and evolutionary
approaches. (Endocrinology 148: 4642–4648, 2007)
THEMELANOCORTIN 4 receptor (MC4R) belongs to thefamily of rhodopsin-like G protein-coupled receptors
(GPCR). MC4R is activated by MSHs and signals via Gs
protein/adenylyl cyclases. The hypothalamic melanocortin
system has been implicated in food intake, energy balance,
and body weight control (1). Consistently, mutations in
MC4R have been made responsible for monogenetic obesity
in humans (2, 3) and othermammals (4, 5). Todate,more than
80 missense, nonsense, and frame-shifting mutations have
been identified or associated with obesity in humans. These
mostly heterozygously occurring MC4R mutations are im-
plicated in 1–6% of early-onset or severe adult obesity cases.
It has been suggested that already a small decrease in overall
MC4R activity can cause obesity (6). Thus, alterations of
MC4R function have been reported to be very multiform,
ranging from a total suppression of receptor activation in
response to agonists to an alteration of the basal activity of
the MC4R. This is in contrast to most other GPCR-related
diseases where pathway inactivation is usually coupled to
prominent functional receptor defects (7). Thismay highlight
the central role of the MC4R for adipostat in humans. How-
ever, one has to consider reasonable problems associating the
genotype with in vitro/in vivo phenotype because an obese
phenotype can result from amultitude of factors. Classically,
the functional relevance of missense mutations is tested in
vitro, e.g. in cAMP assays, radioligand binding studies, and
tests for subcellular distribution of mutant receptors. How-
ever, missense mutations that have been associated with
obesity are also found in nonobese individuals (8). Especially
in cases of no correlation, additional information is required
to substantiate causal genotype/phenotype relations.
The availability of in-depth genome sequence data for
human, chimpanzee, and many other vertebrates as well as
of numerous invertebrates has provided the unique oppor-
tunity to apply comparative approaches to identify con-
served sequences. These new aspects have been imple-
mented in studying structure-function relationships and
even three-dimensional receptor models, e.g. for melanocor-
tin receptors (9, 10) but may be useful also in evaluating
naturally occurring mutations in GPCRs (11).
Herein, we took advantage of the sequence information of
over 60MC4R orthologs (43 were fully or partially cloned for
this study) to reevaluate missense mutations in the MC4R
that have been associated with obesity. We show that most
residues affected by loss-of-function missense mutation are
highly conserved during 450 million years of MC4R evolu-
tion (conservation also shown by Ref. 12). Consequently,
mutations that affect residues highly variable among MC4R
orthologs had no significant influence on receptor function.
However, we identified and functionally reevaluated several
missense mutations that were not compatible with evolu-
tionary conservation data. Our results clearly support the
power of large ortholog sequence data sets when used in
combination with functional testing.
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Materials and Methods
MC4R ortholog identification and site-directed mutagenesis
To analyze the sequence of MC4R orthologs, genomic DNA samples
were prepared from tissue of various species (sources are given in
supplemental Table S1, published as supplemental data on The Endo-
crine Society’s Journals Online web site at http://endo.endojournals.
org). Tissue samples were digested in lysis buffer [50 mm Tris/HCl (pH
7.5), 100mm EDTA, 100mmNaCl, 1% SDS, 0.5mg/ml proteinase K] and
incubated at 55 C for 18 h. DNA was purified by phenol/chloroform
extraction and ethanol precipitation. Degenerated primer pairs (sup-
plemental Table S2) were applied to amplify MC4R-specific sequences.
PCRwere performedwithTaqpolymerase under variable annealing and
elongation conditions. Conditions of a standard PCR were as follows:
genomic DNA (100 ng) used in PCR (50 l) with primers (1.5 m each),
ThermoPol reaction buffer (1), dNTP (250 m, each), and Taq poly-
merase (1 U; NEB, Frankfurt, Germany). The reactions were initiated
with a denaturation at 94 C for 1 min followed by 35 cycles of dena-
turation at 94 C for 30 sec, annealing at 60 C for 30 sec, and elongation
at 72 C for 1 min. A final extension step was performed at 72 C for 10
min. Specific PCR products were directly sequenced and/or subcloned
into the pCR2.1-TOPO vector (Invitrogen, La Jolla, CA) for sequencing.
In case of heterozygosity, allelic separation was performed by subclon-
ing and subsequent sequencing. Sequencing reactions were performed
onPCRproductswith a dye-terminator cycle sequencing kit and applied
on an ABI 3700 automated sequencer (Applied Biosystems, Foster City,
CA).
The full-length human MC4R was inserted into the mammalian ex-
pression vector pcDps and epitope-tagged with an N-terminal hemag-
glutinin (HA) epitope by a PCR-based overlapping fragment mutagen-
esis approach (13). MC4R mutations were introduced into the tagged
version of MC4R using a PCR-based site-directed mutagenesis and
restriction fragment replacement strategy. The identity of the various
constructs and the correctness of all PCR-derived sequences were con-
firmed by restriction analysis and sequencing.
Cell culture and functional assays
COS-7 cells were grown in DMEM supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 g/ml streptomycin at 37
C in a humidified 7% CO2 incubator. Lipofectamine 2000 (Invitrogen,
Groningen, The Netherlands) was used for transient transfection of
COS-7 cells.
[3H]cAMP assay. Cells were split into 12-well plates (1.5  105 cells per
well) and transfected with a total amount of 1 g plasmid DNA/well.
Labeling with 2 Ci/ml [3H]adenine (31.7 Ci/mmol; Pharmacia,
FIG. 1. Structural conservation of amino acid positions in MC4R orthologs. The amino acid sequence of the human MC4R is shown. Positions
conserved in vertebrate MC4R orthologs are depicted in black. Positions that vary only by two amino acids are shown in gray. Positions given
in white are not preserved during MC4R evolution.
TABLE 1. Structural comparison of MC4R orthologs
Domain Length(min/max)
Conservation between mammalian
and fish orthologs
(% identity)
Full-length 323/339 (41) 67.3  2.3 (25:12)
N terminus 35/49 (41) 29.2  6.8 (25:12)
C terminus 23/31 (41) 54.4  7.8 (25:12)
ECL1 21/22 28.3  5.1 (56:16)
ECL2 12 71.5  8.5 (53:14)
ECL3 12 80.3  6.8 (48:17)
ICL1 11 90.5  3.9 (53:17)
ICL2 20 78.5  3.6 (56:15)
ICL3 21 69.2  7.0 (53:18)
TMD1 24 68.4  3.9 (30:14)
TMD2 23 92.7  3.7 (53:17)
TMD3 23 84.4  3.5 (55:16)
TMD4 24 61.2  4.4 (54:14)
TMD5 22 85.6  5.9 (53:16)
TMD6 24 84.4  3.5 (54:17)
TMD7 23 90.1  3.0 (33:16)
The sequence information of 76 full-length or partially identified
MC4R orthologs (see supplemental Table 1) was used to determine
global and more distinct structural parameters. Segment lengths
(minimum/maximum) and the structural conservation between fish
and mammalian orthologs (given as percent identity determined by
Clustal W) are shown. For comparing domain conservation of other
GPCR, seeRef. 16.Numbers given in parentheses indicate the number
of orthologs used for analysis. Data are given as means  SD.
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Freiburg, Germany) was performed 48 h after transfection. One day
later, cAMP accumulation assays were performed. Cells were washed
once and incubated in serum-free DMEM containing 1 mm 3-isobutyl-
1-methylxanthine (Sigma, Munich, Germany) in the absence or in in-
creasing amounts of agonists NDP--MSH (Sigma), -MSH, -MSH,
-MSH, or ACTH (kindly provided by Dr. P. Henklein, Charite´ Uni-
versita¨tsmedizin Berlin, Institute of Biochemistry) for 1 h at 37 C. The
reactions were stopped by aspiration of medium, and intracellular
cAMP was released by the incubation with 1 ml 5% trichloric acid and
measured by anion-exchange chromatography as described previously
(14).
ALPHAScreen cAMP assay. As a second test, cAMP content of cell ex-
tracts was determined by a nonradioactive cAMP assay based on the
ALPHAScreen technology (Perkin-Elmer Life Science, Inc., Boston, MA)
(11). Thus, cells were split into 50-ml cell culture flasks (1 106 cells per
flask) and transfectedwith a total amount of 4g plasmid. One day after
transfection, cells were seeded in 48-well plates (5  104 cells per well).
Stimulation of cells with agonists was performed 48 h after transfection
as described above. The reactions were stopped by aspiration of media,
and cells were lysed in 50 l lysis buffer (see ALPHAScreen manual)
containing 1 mm 3-isobutyl-1-methylxanthine. From each well, 5 l
lysate were transferred to a 384-well plate. Acceptor beads (in stimu-
lation buffer without 3-isobutyl-1-methylxanthine) and donor beads
were added according to the manufacturers’ protocol. cAMP accumu-
lation data were analyzed by the GraphPad Prism program (GraphPad
Software, San Diego, CA).
Binding assay. One day after transfection, cells were seeded in 48-well
plates for assay. The number of cells was chosen to obtain a 5–10%
binding of the radioligand. Cells were assayed 48 h after tranfection in
competition binding assays using [125I]NDP--MSH as tracer. Radioli-
gand was bound in a buffer composed of 0.5 ml 50 mm HEPES buffer
(pH 7.2) supplemented with 1 mm CaCl2, 5 mm MgCl2, and 0.1% BSA
and displaced in a dose-dependent manner by unlabeled ligands. The
assaywas performed in duplicate for 3 h at 25 C and stopped bywashing
twice in the buffer. Cell-associated, receptor-bound radioligands were
determined by the addition of lysis buffer (48% urea, 2% Nonidet P-40
in 3 m acetic acid).
An indirect cellular ELISA was used to ligand-independently esti-
mate cell surface expression of receptors carrying an N-terminal HA tag
(15).
Results and Discussion
Structural and functional conservation of MC4R orthologs
in vertebrates
Public sequence databases were mined for full-length fish
and mammalian MC4R orthologs. The overall identity be-
tween full-length mammalian (25 species) and fish (12 spe-
cies) is 67.3 2.3% (see Table 1). During 450 million years of
evolution, 173 (52%) of all amino acid residues in theMC4R
remained unchanged between these selected species (sup-
plemental Fig. S1). In comparison, rhodopsin presents an
overall identity of 77.4 2.2% between fish and mammalian
orthologs (16). However, the overall structural conservation
of MC4R is still remarkably high when compared with large
ortholog data sets of other GPCR such as the lyso-phospha-
tidylserine receptor GPR34 (16).
We further increased the sequence information by fully or
partially cloning additional MC4R orthologs (see supple-
mental Table S1). The sequence information of 76 full-length
or partially identified MC4R orthologs enabled us to deter-
mine global and more distinct structural parameters of
MC4R that are relevant for maintaining the receptor struc-
ture and its agonist binding and signal transduction abilities.
First, we found no length variations within the extracellular
and intracellular loops except extracellular loop 1 (ECL1). In
platypus and all fish orthologs, ECL1 contains one additional
amino acid. ECL1 is the most diverse region between mam-
malian and fish MC4Rs (10). Second, the N terminus is most
diverse between vertebrate orthologs (see Table 1), clearly
indicating less specific relevance in ligand binding and re-
ceptor activity. Third, the C terminus contains at least one
Cys residue that allows anchoring via palmitoylation; how-
ever, a proposed di-leucinemotive equivalent (Ile316/Ile317 in
human MC4R) (17) is less preserved during evolution. Ile316
was found substituted by Met and Ile317 by Met, Cys, Phe,
and Val in vertebrate MC4R orthologs. Fourth, transmem-
brane domain 1 (TMD1) and TMD4 display the lowest con-
servation (see Table 1 and Fig. 1), whereas the other TMDs
are almost equally conserved at levels ofmore than 82%. This
picture of conservation is very similar to rhodopsin but dif-
fers significantly from other GPCR, e.g. the lyso-phosphati-
dylserine receptor GPR34, where only TMD3 and TMD7
show high conservation (16). This indicates that proper
MC4R function requires a reasonably higher number of de-
terminants and intramolecular constraints than other GPCR.
Fifth, it is of interest to note that all five extracellular Cys
residues (Cys40, Cys196, Cys271, Cys277, and Cys279) are
conserved during vertebrate MC4R evolution. This indicates
importance even for Cys40 and Cys279, although experi-
mental evidence in support of their functional relevance is
not available yet (13).
Evaluation of naturally occurring mutations in the
human MC4R
To date, about 70 missense variants (60 amino acid posi-
tions) of the human MC4R have been described (supple-
mental Table S3). About 46% missense variants were re-
ported to have a partial or complete loss of function, about
44% displayed no differences to the wild-type receptor when
studied in in vitro tests, and about 10% are not tested yet
(Table 2). Taking advantage of this information, we analyzed
the correlation of in vitro assay results and structural con-
TABLE 2. Function-conservation relationship of natural
occurring mutations in MC4R
Conservation of the
position
Wild-type
function
Partial or loss
of function
2 Amino acids 18a 3
2 Amino acids 8 9
1 Amino acid 5 24b
More than70missensemutations at 60 positionswithin thehuman
MC4R have been described. About 90% of all mutations were func-
tionally tested. The table gives a correlation between the functional
consequence of individual mutations and the evolutionary conserva-
tion of the mutated position. The complete list of missense mutations
included in the analysis and the references are given in supplemental
Table S3. For several mutations, different functional consequences
were reported (see supplemental Table S3). Therefore, we considered
all functional phenotypes by including and counting them individu-
ally. The evolutionary conservation of each mutated position was
determined by aligning all MC4R orthologs, and the variability of the
position was categorized in three groups from no variation (one amino
acid) to high variation (more than two amino acids) in vertebrate
orthologs. P values were determined by Fisher exact test.
a P  0.05.
b P  0.001.
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servation of the positions found to be mutated in a human
individual.
However, conservation as well as variability of distinct
positions can only be properly interpreted in the light of
functional data of different orthologs. Therefore, a number of
mammalian and fish MC4R orthologs were stimulated with
the natural agonists -MSH, -MSH, -MSH, andACTH and
functionally analyzed in cAMP assays (ALPHAScreen cAMP
assay, see Materials and Methods). As shown in Table 3, we
found only minor differences in basal activity. For control
purposes, the human MC1R was included, which is known
for high basal activity. Although there were obviously some
differences in agonist potencies between the orthologs, e.g.
lower potency of -MSH at sea lion and bat orthologs (Table
3), we consider these differences as minor and probably
physiologically not relevant (potency differences less than
10-fold). Several differences become relative when ratios are
calculated (see Table 3). -MSH appears to be an exception,
at least at the halibut ortholog. However, the potency of
-MSH is always the lowest among the tested MC4R or-
thologs. To verify these results, we performed [3H]cAMP
accumulation assays with the same MC4R orthologs and
-MSH,-MSH, andNDP--MSHas agonists,which yielded
essentially similar results (see supplemental Table S4). Fi-
nally, radioligand displacement assays were performed.
Consistent with the functional data, only minor differences
[less than 10-fold differences in IC50 values, except Fat
sandrat/human (ACTH), 15-fold)] were found (Table 4).
These data indicate that structural differences have no major
effects on receptor function, at least for these orthologs.
Previous studies with the V2 vasopressin receptor have
shown that 88% of inactivating (disease-causing) missense
mutations hit fully or almost fully conserved positions (7).
There were only a few missense mutations, mainly to Cys
mutations in the ECL (11), which cause receptor inactivation
at positions with low conservation. As summarized in Table
2, 92% of all partial and complete loss-of-function mutations
occur at positions that are highly conserved during evolu-
tion, and 58% of all mutations with no functional effect are
found on positions that vary in more than two amino acids
between orthologs. However, there are a reasonable number
of mutants with wild-type receptor properties carrying sub-
stitutions at 100% conserved residues (Val50Met, AL154Asp,
Ile226Thr, Asn274Ser). One may speculate that the number of
ortholog sequences is still insufficient to detect even rare
functionally tolerated substitutions in wild-type MC4R or-
thologs. On the other hand there are several substitutions
that have been claimed to be inactivating but naturally occur
in other vertebrate MC4R orthologs (Val95Ile, Ala175Thr,
Asn240Ser, Val253Ile). One may speculate that a reduced
MC4R activity may be of advantage in the affected species or
that the inactivating substitution is functionally rescued in
the sequence context of the specific ortholog. Furthermore,
one cannot exclude errors in in vitro testing of the mutant
receptors, and careful reevaluation is needed. One candidate
for reevaluation is Val95Ile. This mutation in TMD2 was
identified in an obese patient and proposed to cause MC4R
inactivation by two independent groups (18, 19). T
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Evaluation of mutant MC4R on the basis of evolutionary
and functional data
In most other vertebrates, Val95 is preserved, and only
armadillo and polar bear MC4R contain Ile95. It is of interest
because the next relatives of the polar bear all have only Val95
(Fig. 2). Polar bears and brown bears split about 300,000 yr
ago from a common ancestor (20), and the Ile95 variant be-
came highly frequent (six individuals analyzed all contain
Ile95) during this evolutionary short time in the polar bear
linage. Reflecting the loss of functionality of the Val95Ile
variant in the human MC4R (18, 19), one may ask for ad-
vantages the polar bear would have from an inactive MC4R.
As a maritime mammal, increase of body fat would be ad-
vantageous with respect to temperature isolation and buoy-
ancy in water. Furthermore, the energy demand is increased
in a polar climate, and one may speculate that the energy
storage in time of food surplus may be improved when
MC4R is less active.
As already tested in both cAMP assays (Table 3 and sup-
plemental Table S4) the polar bear MC4R showed a robust
agonist-dependent cAMP formation, and comparison with
the brown bear ortholog (carrying the humanVal95) revealed
no differences in functional assays. Except for the slightly
lower Emax value of polar and brown bear orthologs (Table
5), no differences were obvious when comparedwith human
MC4R. Similar results were obtained in transiently trans-
fected HEK-293 and CHO-K1 cells (data not shown). Fur-
thermore, no differences were seen in ligand-independent
measurements of receptor cell surface expression levels
(ELISA, Table 5). To analyze whether the Val95Ile substitu-
tion has a functional consequence at all, we generated the vice
versa mutants in human MC4R (Val95Ile) and polar bear
MC4R (Ile95Val) and compared the function with the respec-
tive wild-type receptor orthologs. As shown in Fig. 3 and
Table 5, themutantswere indistinguishable from their parent
wild-type receptors. In sum, in the experimental settings
used in the present study, we did not obtain evidence for a
functional difference between Val95 and Ile95 variants.
We extended our reevaluation to other MC4R mutations
that have been found in obese patients. Asn274 is fully con-
served among vertebrate MC4R, and mutation to Ser was
found in obese patients (21). Previous functional studies re-
vealed wild-type function for this mutation (19, 22). The
positionAsn274 is not conserved onlywithinMC4R orthologs
but also in all other members of the melanocortin receptor
family except for mammalian MC1R where Asn274 is sub-
stituted byHis. In our functional tests, the basal cAMPvalues
and EC50 values for -MSH and NDP--MSH were un-
changedwhen comparedwith thewild-typeMC4R.Whereas
the reduction in the Emax valueswas insignificant, cell surface
expression level of Asn274Ser was significantly reduced (Ta-
ble 5). These results were independently verified with the
[3H]cAMP accumulation assay (Tarnow, P., H. Brumm, and
H. Biebermann, supplemental Table S5). Similarly, substitu-
tion of Asn274 by Cys displayed unchanged potency and
affinity and only aminor reduction in Emax values. However,
the Bmax value was reduced to 61% of the wild-type MC4R
FIG. 2. Amino acid alignment of TMD2
of bears. The amino acid sequence of the
human and bear MC4R orthologs are
shown. Positions not conserved in the
given orthologs are depicted in black.
The number of individuals sequenced is
given in parentheses.
TABLE 4. 125INDP--MSH displacement binding for selected MC4R orthologs
Ortholog
125INDP--MSH displacement binding, IC50 (nM) Ratio,
-:-:-MSH:ACTH
Cell surface expression
(% of hMC4R)-MSH -MSH -MSH ACTH
Human 154.3  10.6 (3) 276.2  64.3 (5) 915.3  235.6 (3) 293.3  5.3 (2) 1:1.8:5.9:2.5 100 (8)
Mink whale 130.8  17.4 (3) 350.9  72.2 (5) 1261.6  410.4 (3) 155.2  95.3 (2) 1:2.7:9.6:2.8 111  16 (3)
Sea lion 85.1  1.0 (3) 216.7  34.8 (5) 589.4  209.8 (3) 95.5  42.4 (2) 1:2.5:6.9:2.9 95  3 (3)
Sloth 99.8  9.0 (3) 243.3  64.2 (5) 804.2  287.9 (3) 106.2  44.2 (2) 1:2.4:8.1:1.4 92  7 (3)
Bat 82.4  7.1 (3) 233.8  52.0 (5) 231.5  76.4 (3) 82.3  13.6 (2) 1:2.8:2.8:1.8 101  8 (3)
Hyrax 97.2  23.9 (3) 209.4  60.9 (5) 746.5  412.4 (3) 129.8  10.3 (2) 1:2.2:7.7:0.3 101  8 (3)
Fat sandrat 82.4  4.9 (3) 153.0  30.8 (5) 379.2  121.3 (3) 20.7  4.6 (2) 1:1.9:4.6:1.2 88  11 (3)
Polar bear 177.8  16.4 (3) 277.0  77.0 (5) 1332.0  459.2 (3) 263.7  98.8 (2) 1:1.6:7.5:0.8 108  8 (8)
Halibut 141.5  11.0 (3) 291.8  38.4 (5) 1351.8  199.8 (3) 284.0  108.4 (2) 1:2.0:9.3:2.1 106  16 (3)
For functional characterization, COS-7 cells were transiently transfectedwithMC4R constructs, and 125INDP--MSHdisplacement binding
assays were performed as described in Materials and Methods. IC50 values were determined from concentration-response curves of agonists
(agonists 10 pM to 1 M) using GraphPad Prism. Data are presented as means  SEM of independent experiments (number indicated in
parentheses), each carried out in duplicate. Ratios were determined. IC50 for -MSH for each ortholog was set as 1. Cell surface expression levels
of MC4R orthologs were measured by a cell surface ELISA. Specific OD readings (OD value of HA-tagged construct minus OD value of
GFP-transfected cells) are given as a percentage of wild-type HA-tagged hMC4R. The nonspecific OD value (GFP) was 0.195  0.078 (set as
0%), and the OD value of the wild-type HA-tagged hMC4R was 0.895  0.258 (set as 100%). The number of independent experiments, each
carried out in quadruplicate, is given in parentheses.
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(13). Our data indicate that mutation of Asn274Ser disturbs
proper cell surface trafficking.
Ala175Thr (23–25), Phe202Leu (26), and Asn240Ser (26) con-
tain substitutions that naturally occur in fish (Thr175, Ser240)
and bat (Leu202) MC4R orthologs. As shown in Table 5, basal
cAMPandEC50 values of themutantswere indistinguishable
from wild-type MC4R. Phe202Leu and Asn240Ser showed
small reductions in Emax values and cell surface expression
levels.
Conclusion
Over 450 million years of vertebrate evolution, the MC4R
shows high structural and functional conservation. Its phys-
iological importance is further reflected by the fact that no
pseudogenes are identified yet. Large sets of ortholog se-
quence data are helpful for the interpretation of clinically
relevant mutations. We clearly show that there is a strong
correlation between positional conservation and the func-
FIG. 3. Functional characterization of
mutations at position 95 in human and
polar bear MC4R. For functional charac-
terization of the wild-type (human and po-
lar bear) and of mutant MC4R constructs,
cDNAs were cloned into the expression
vector pcDps and tested for agonist-in-
duced cAMP accumulation. Forty-eight
hours after transfection, cells were stim-
ulated with increasing concentrations of
-MSH and NDP--MSH. Intracellular
cAMP was measured with AlphaScreen
cAMP assay (seeMaterials and Methods).
Data are given as mean  SEM of three to
seven experiments (see Table 5), each per-
formed in duplicate.
TABLE 5. Functional characterization of human and bear MC4R orthologs/mutants
MC4R ortholog/mutant
ALPHAScreen cAMP assay
Cell surface expression
(% of hMC4R)
-MSH NDP--MSH
Basal cAMP
(fold over hMC4R
WT basal)
Emax
(fold over hMC4R
WT basal)
EC50
(nM)
Basal cAMP
(fold over hMC4R
WT basal)
Emax
(fold over hMC4R
WT basal)
EC50
(nM)
Human 1 11.2 1.1 9.9 2.1 (11) 1 16.8 3.3 0.9 0.3 (7) 100 (8)
Human Val95Ile 0.9 0.1 10.8 2.8 6.7 1.1 (7) 1.1 0.1 15.2 4.6 1.5 0.4 (6) 96 7 (6)
Polar bear 0.5 0.1 7.2 1.0 11.8 2.7 (7) 0.5 0.1 9.5 2.9 0.8 0.2 (3) 108 8 (8)
Polar bear Ile95Val 0.5 0.1 7.1 1.3 7.2 1.7 (4) 0.8 0.1 8.7 1.9 0.4 0.1 (4) 105 12 (6)
Brown bear 0.6 0.1 7.7 1.0 14.6 5.0 (9) 0.9 0.2 8.8 3.6 1.2 0.6 (4) 97 3 (5)
Ala175Thr 1.2 0.2 12.2 4.5 5.4 1.1 (9) 1.6 0.2 16.0 3.8 0.9 0.2 (7) 103 6 (6)
Phe202Leu 0.7 0.1 9.2 1.7 6.4 1.7 (9) 1.2 0.1 13.9 3.3 0.9 0.3 (6) 76 4 (6)
Asn240Ser 1.1 0.2 7.7 1.3 8.1 3.4 (10) 1.5 0.2 14.6 2.1 1.4 0.5 (7) 92 1 (2)
Asn274Ser 1.1 0.1 8.8 1.5 4.5 0.6 (10) 1.4 0.1 12.6 2.0 0.9 0.4 (7) 61 6 (5)
For functional characterization, COS-7 cells were transiently transfected with MC4R constructs, and nonradioactive cAMP assays were
performed as described in Materials and Methods. Emax and EC50 values were determined from concentration-response curves of agonists
(agonists 10 pM to 10 M) using GraphPad Prism. Data are presented as means  SEM of independent experiments (number indicated in
parentheses), each carried out in duplicate. cAMP levels (58.2 8.8 amol/cell) of nonstimulated humanMC4R wild type served as basal values.
Cell surface expression levels of the wild-type and mutant MC4R were measured by a cell surface ELISA. Specific OD readings (OD value of
HA-tagged construct minus OD value of GFP-transfected cells) are given as a percentage of wild-type HA-tagged hMC4R. The nonspecific OD
value (GFP) was 0.195 0.078 (set as 0%), and the OD value of the wild-type HA-tagged hMC4R was 0.895 0.258 (set as 100%). The number
of independent experiments, each carried out in quadruplicate, is given in parentheses. WT, Wild type.
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tional relevance of mutation affecting a distinct position.
Because of the manifold factors causing obesity, phenotype-
genotype correlations are difficult to perform for mutations
in MC4R. Evaluation of naturally occurring substitutions in
MC4R on the basis of only in vitro functional tests has a
limited power. The combination of functional and evolu-
tionary data provides several advantages in interpretingmu-
tations as shown by our reevaluation of selected MC4R
mutants.
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